An Ethical Cannabis-Driving Review Distinguished Patient Counseling From Jurisdiction-Specific Reporting Rules
A 2023 ethical review emphasized informing and caring for patients while treating reporting questions as dependent on legal and policy context. Its framework is not itself a statement of a clinician's legal duty in a particular jurisdiction.
The source was an interpretive ethical analysis
The review synthesized literature to frame primary-care decisions about suspected cannabis-impaired driving. That differs from a trial validating an impairment test or an official source establishing current reporting law.
The patient discussion requires more than a positive test
The framework considered use pattern, formulation, dose, tolerance and withdrawal alongside driving. These topics help organize a clinical conversation. A chemical exposure result alone cannot determine all relevant functions or establish the appropriate response.
Care and reporting remain distinct decisions
The authors emphasized therapeutic relationships, prevention, harm reduction and specialist support. They also stated that specific recommendations depend on jurisdiction. Ethical reasoning can inform an approach without establishing when a mandatory disclosure rule applies.
Interpreting the evidence
This review supports a patient-centered framework and careful separation of scientific evidence, ethical judgment and law. It does not provide current legal advice or establish that every cannabis disclosure or positive test requires reporting to authorities.
Related reading: interpreting cannabis tolerance claims.
Research reference
Huerne K; Ells C; Grad R; Filion KB; Eisenberg MJ (2023). Cannabis-Impaired driving: ethical considerations for the primary care practitioner. Annals of medicine. doi:10.1080/07853890.2022.2151716.
This analysis draws on the supplied review abstract.
